Oncology Servier’s ASCO 2025 data: Advancing IDH-mutated cancer treat... At ASCO 2025, Servier’s Becky Martin discusses IDH-mutated cancers, including key insights on Tibsovo & Voranigo, and the implications for patients.
Oncology Breaking barriers to CAR T-cell therapy: The vision for expa... Live from ASCO 2025: Prof. Dr Jason Westin discusses CAR-T Vision, patient access, and the push to expand therapy reach in rare blood cancers.
News ASCO 25: Sanofi hopes on-body delivery will boost Sarclisa Can a new on-body injector version of Sanofi's Sarclisa help it claim market share from J&J's rival top-selling Darzalex in multiple myeloma?
News ASCO 25: J&J combo pill may see wider use in prostate cancer AMPLITUDE study of J&J's Akeega could extend the use of PARP inhibitors to hormone-responsive prostate cancer.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
